# Hepion Pharmaceuticals, Inc. (HEPA) · Edgar & Edgarette company card

> Hepion Pharmaceuticals (HEPA) reported revenue of $0 million in FY2023, operating margin null against a -3.8% median for pharmaceutical preparations, equity 40.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1583771 · fiscal year ended 2023-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/HEPA) · [JSON](https://www.pops4.com/boards/company/HEPA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$41M |
| Capital spending | $14,304 |
| Free cash flow | −$41M |
| Cash | $15M |
| Long-term debt | — |
| Total assets | $18M |
| Total equity | $7M |
| Equity ÷ assets | 40.2% |
| Return on equity | -672.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -53.33 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · filed auditor change in the last 12 months; operating cash flow was negative (-$3.3M in FY2025)

## Edgarette's reading

Exposure: revenue $0K (FY2023). Experience: one year on record; operating margin null, up from null. Soundness: equity 40.2% of assets, return on equity -672.0%. Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item 4.01 Auditor change: 1, latest 2026-09-28 ([filing](https://www.sec.gov/Archives/edgar/data/1583771/000149315226044432/0001493152-26-044432-index.htm))
- Item 5.02 Director or officer change: 6, latest 2026-10-09 ([filing](https://www.sec.gov/Archives/edgar/data/1583771/000149315226046546/0001493152-26-046546-index.htm))

## Recent filings

- 8-K · filed 2026-10-09 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1583771/000149315226046546/0001493152-26-046546-index.htm)
- 8-K · filed 2026-10-02 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1583771/000149315226045447/0001493152-26-045447-index.htm)
- 8-K · filed 2026-09-28 · 4.01 Changes in Registrant's Certifying Accountant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1583771/000149315226044432/0001493152-26-044432-index.htm)
- 8-K · filed 2026-09-08 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1583771/000149315226041801/0001493152-26-041801-index.htm)
- 8-K · filed 2026-08-27 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1583771/000149315226040411/0001493152-26-040411-index.htm)
- 8-K · filed 2026-08-20 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1583771/000149315226039488/0001493152-26-039488-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001583771.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1583771

## Cite

POPS4, Edgar & Edgarette: Hepion Pharmaceuticals, Inc. (HEPA) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/HEPA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2023, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.